Contraception

Phase I Trials Evaluate Seven-Day Combination Patches

Published in Women's Health Weekly, September 13th, 2001

Agile Therapeutics, Inc. (formerly Levotech, Inc.), announced that two Phase I clinical trials have begun enrollment. The goal of these trials is to evaluate the safety of two new seven-day transdermal formulas for birth control.

Approximately 15 subjects will be evaluated in each of the two trials. Each trial will run 30 days and will measure blood levels of levonorgestrel and ethinyl estradiol. When these trials are completed, Phase II trials will begin with each formula to determine ability to inhibit ovulation.

Agile Therapeutics currently is conducting two Phase II trials using its original formulation in 7.5 cm² and 9...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry